Blog

Blog 2017-09-28T20:01:25+00:00
Erin Newburn, MS, PhD

Refining neoantigen load

Tumor mutational burden (TMB) has now been established as a positive predictive biomarker of response to immune checkpoint inhibitors with more studies demonstrating correlations between the overall mutational landscape and clinical benefit ...READ MORE
Sean Michael Boyle, MS, PhD Erin Newburn, MS, PhD |

Overcoming the obstacles of neoantigen identification

Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.READ MORE
Erin Newburn, MS, PhD

Resistance to immunotherapy: The elusive routes of immune escape

Achieving a durable clinical response is the ultimate goal in immuno-oncology clinical trials. With immunotherapies showing long-lasting, unprecedented responses in cancer indications such as melanoma and Non-Small Cell Lung Cancer (NSCLC), these immune-boosting drugs seem to be displaying genuine advancesREAD MORE
Erin Newburn, MS, PhD

Is timing everything?

Unlike targeted therapies, there tends to be general agreement that it is unlikely that a single predictive biomarker in tumor biopsies will be found for determining response to immunotherapies.READ MORE
Toby Ward, PhD

The importance of cellular neoantigens for immuno-oncology in virus-associated cancers

Approximately 12% of human cancers are associated with viral infection, including a majority of cervical cancers, Merkel cell carcinomas, and oropharyngeal cancer cases, along with significant proportions of other head and neck cancers and hepatocellular carcinomas.READ MORE